

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

BRECKENRIDGE PHARMACEUTICAL, INC.	)	
	)	C.A. No. 1:24-cv-00571-GBW
	)	
Plaintiff,	)	
	)	
v.	)	
	)	
HETERO USA, INC., HETERO LABS	)	
LIMITED UNIT-III, HETERO LABS	)	
LIMITED, and CAMBER	)	
PHARMACEUTICALS, INC.	)	
	)	
Defendants.	)	

**PLAINTIFF BRECKENRIDGE PHARMACEUTICAL, INC.'S FIRST
SET OF REQUESTS FOR ADMISSION (NOS. 1-17)**

Pursuant to Federal Rules of Civil Procedure 26 and 34, Plaintiff Breckenridge Pharmaceutical, Inc. by and through its attorneys, propound the following requests for admission to Defendants Hetero USA, Inc., Hetero Labs Limited Unit-III, Hetero Labs Limited, and Camber Pharmaceuticals, Inc. (collectively referred to as “Hetero” “You” or “Your”).

DEFINITIONS

Plaintiff incorporates by reference the definitions included in Plaintiff’s Second Set of Interrogatories (Nos. 8-20).

REQUESTS FOR ADMISSION

REQUEST NO. 1: Admit that You began marketing Your Dabigatran Products in the United States in September 2022.

REQUEST NO. 2: Admit that Your Dabigatran Products contain at least two distinct types of particles.

CERTIFICATE OF SERVICE

I hereby certify that on October 18, 2024, true and correct copies of the foregoing document were caused to be served on the following counsel of record as indicated:

BY ELECTRONIC MAIL

Kenneth L. Dorsney
Cortlan S. Hitch
Morris James LLP
500 Delaware Ave., Ste. 1500
Wilmington, DE 19801

BY ELECTRONIC MAIL

Dennies Varughese
Adam C. LaRock
Alexander V. Alfano
Ryan N. Kaiser
Christopher Coleman
Christopher M. Gallo
Sterne, Kessler, Goldstein & Fox, P.L.L.C.
1101 K Street, N.W.
10th Floor
Washington, D.C. 20005

/s/ Kelly E. Farnan

Kelly E. Farnan (#4395)
farnan@rlf.com